Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H34O5 |
| Molecular Weight | 354.481 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@H]1CCCCCCC(O)=O
InChI
InChIKey=GMVPRGQOIOIIMI-JCPCGATGSA-N
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16-,17+,19+/m0/s1
8-Epiprostaglandin E1 (8-iso-PGE1) arises by isomerization of PGE1. This isoprostane found in human semen. 8-iso-PGE1 has very low biological activity relative to PGE1. Intravenous administration of 8-iso-PGE1 decreased systemic arterial pressure slightly and increased heart rate and myocardial contractile force slightly. The magnitude of the systemic hypotensive effect of 8-iso-PGEl was equivalent to approximately 1/125 to 1/250 of that of PGE1 in dogs. On the other hand, the pulmonary hypertensive action of 8-iso-PGE1 was 5 times greater than that of PGE1. 8-iso-PGE1 is an agonist of prostanoid TP receptor. It was proposed as a prostaglandin D2 receptor antagonist for use in the treatment of androgenic alopecia.
Approval Year
Sample Use Guides
Dog: Intravenous - 0.25-16 ug/kg
Intra-arterial - 2 ug/kg
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5283212
Created by
admin on Sat Dec 16 08:00:19 GMT 2023 , Edited by admin on Sat Dec 16 08:00:19 GMT 2023
|
PRIMARY | |||
|
84W5RE239W
Created by
admin on Sat Dec 16 08:00:19 GMT 2023 , Edited by admin on Sat Dec 16 08:00:19 GMT 2023
|
PRIMARY | |||
|
DTXSID901185206
Created by
admin on Sat Dec 16 08:00:19 GMT 2023 , Edited by admin on Sat Dec 16 08:00:19 GMT 2023
|
PRIMARY | |||
|
21003-46-3
Created by
admin on Sat Dec 16 08:00:19 GMT 2023 , Edited by admin on Sat Dec 16 08:00:19 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
